Our Company

This study identifies the total healthcare allowed spending and patient out-of-pocket costs from the year before diagnosis with a blood cancer through the three years after diagnosis.

This research compares the demographics, comorbidities, and medical costs of newly diagnosed patients and those who were previously diagnosed with HCV infection after the Centers for Disease Control and Prevention expanded its HCV testing recommendations to target adults born between 1945 and 1965.

Understanding pharmacy spending by heart failure patients requires an evaluation of the complex interactions between members, payers, manufacturers, and the government in Part D.

This article explains the finances associated with pharmaceutical manufacturer rebates and their impact on health insurer coverage decisions.

This report analyzes the impact of the per-prescription cost-sharing cap for non-catastrophic plans on projected prescription drug spending across the California individual and small group markets.

Key changes to the Medicare Part D program will affect the donut hole in 2019, and this paper discusses the implications for stakeholders.

This report examines the Colorado and Montana markets before and after the guidance regarding fixed dollar prescription drug copays and no prescription drug deductible or coinsurance requirements in certain health plans.

Understanding pharmacy spending by heart failure patients requires an evaluation of the complex interactions between members, payers, and manufacturers in Part D.

This report characterizes the costs to cancer patients and their health plans for three cancers: breast, lung, and colorectal.

This report uses drug formulary data covering over 150 million lives in the U.S. to examine trends in the use of prior authorization, step therapy, and formulary exclusion in commercial formularies for the years 2011 to 2016.